VTVT News and Press, vTv Therapeutics Inc. From 07/25/22

HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidiary of CinRx Pharma, LLC (“CinRx”). Under the terms of the...

Morgan Stanley says that global obesity sales in 2030 could reach $54B, driven by Eli Lilly ( NYSE: LLY ) and Novo Nordisk’s ( NVO ) ( OTCPK:NONOF ), while other large-cap pharma players closely watch their dominance amid emerging data from new biotechs. Obesi...

HIGH POINT, N.C., June 04, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that the results from the JDRF-supported mecha...

Aravive (NASDAQ:ARAV) has appointed Rudy Howard to succeed Vinay Shah as Chief Financial Officer, effective immediately. Vinay Shah has stepped down for personal reasons but will remain with the company as an advisor to ensure a smooth transition. Prior to joining Aravive, Mr. Howar...

3 Hot Penny Stocks to Add to Your Watchlist in June With a relatively flat trading day for penny stocks and blue chips, stocks were down slightly in early trading. The stock market has been on a bullish tear in the past few trading days, but it appears that the rally is extremely volati...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips vTv Therapeutics (NASDAQ: VTVT ) is getting funding from G42 Investments . That includes an initial $12.5 million payment. The agreement has them working together on drug development. Source: NicoElNino / S...

Clinical-stage biotech vTv Therapeutics (NASDAQ:VTVT) climbed ~87% in the pre-market Wednesday after the company announced collaboration and license agreement with affiliates of UAE-based health tech firm G42 Healthcare for its lead candidate TTP399 targeted at type 1 diabetes. Per ...

HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (“G42 Investments”). Under the terms of the agreements, G42 Investment...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reduced focus on Covid-19 and less worries about interest rates should push many biotech stocks higher. vTv Therapeutics ( VTVT ) has strong positive catalysts in the medium term and the long term. Novavax ( ...

vTv Therapeutics press release (NASDAQ:VTVT): Q1 GAAP EPS of -$0.10. Revenue of $2M (+100.0% Y/Y). The Company’s cash position as of March 31, 2022, was $12.1 million compared to $13.4 million as of December 31, 2021. For further details see: vTv Therapeutics GAAP EPS of -$0.10, ...